Unlikely to cause harm — often a labeling or packaging issue.
Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
| Brand name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Generic name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE |
| Distributed by / for | Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430 |
| NDC | -68462-878-30 |
| Full product label | Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-878-30; (b) 100-count bottle, NDC-68462-878-01; (c) 500-count bottles, NDC-68462-878-05; Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, Inda. Manufactured for: Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430. |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA |
| Distribution | Nationwide in the USA |
| Quantity | 11,136 bottles |
| Recall initiated | 2025-11-21 |
| Report date | 2025-12-10 |
| Recall completed | — |
| Recall number | D-0199-2026 |
| Classification | Class III |
| FDA status | Ongoing |
| Origin on file | Elmwood Park NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗